Table 4.
Baseline laboratory data of patients.
| Blood tests | Unit | Frequency (n/%) |
|---|---|---|
| Blood group | O + | 20 (37.7%) |
| O – | 2 (3.8%) | |
| B + | 10 (18.9%) | |
| B – | 2 (3.8%) | |
| A + | 16 (30.2%) | |
| A – | 3 (5.7%) | |
| RBC | 1012/L | 4.9 (±0.5) |
| WBC | 109/L | 5,180 (±2017) |
| Platelets | 109/L | 174 (±78) |
| Creatinine | mg/dL | 1.55 (±1.19) |
| Serum Albumin | g/dL | 3.9 (±1.1) |
| Total Bilirubin | mg/dL | 0.55 (±0.40) |
| AST | IU/L | 61 (±58) |
| ALT | IU/L | 66 (±67) |
| ALP | IU/L | 230 (±128) |
| MELD score | Score | 18 (±3) |
| HCV genotype | 1a | 17 (32.1%) |
| 1b | 9 (17%) | |
| 2a | 2 (3.8%) | |
| 3a | 17 (32.1%) | |
| 3b | 5 (9.4%) | |
| 4 | 3 (5.7%) | |
| HCV viral load | (log IU/mL) | 6.00 (±1.21) |
BMI, Body mass index; DAA, Direct-acting antivirals; SOF, Sofosbuvir; LDV, Ledipasvir; DCV, Daclatasvir; MELD, Model for End-Stage Liver Disease; RBC, red blood cells; WBC, white blood cells; Cr, creatinine; AST, aspartate aminotransferase; ALT, alanine transaminase; ALP, alkaline phosphatase.